Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol

Bone Marrow Transplantation
J-P LotzGroupe d' Intensification des traitements des Tumeurs Ovariennes (ITOV Group)

Abstract

Topotecan has demonstrated activity in ovarian carcinomas. In order to increase the tumour response rate and to define the maximum tolerated dose (MTD) of topotecan, we decided to develop a high-dose phase I regimen supported by stem cell support. High-doses schedules using a 1-day single administration have MTDs of 10.5 (24 h continuous infusion (CI)) or 22.5 mg/m2 (30 min infusion). Five-day CI induces grade IV mucositis at high doses (MTD<12 mg/m2). We chose to administer topotecan in a 5-day schedule with a 30 min daily infusion. Patients were scheduled to receive one cycle of therapy. The first dose level was 4.0 mg/m2/day x 5 days. Limiting toxicities were defined as toxic death, grade IV non-haematopoietic or haematopoietic toxicity >6 weeks. From August 1998 to April 2002, 49 patients were included. Forty-three patients have completed one course and 15 have received two cycles. One patient treated at level 7 mg/m2/day died of sepsis. Median duration of grade IV neutropenia was 9 days. Two episodes of grade IV diarrhoea were observed at level 9.5 mg/m2/day. Pharmacokinetic data were linear within the dose range of 4-9.0 mg/m2/day. The MTD was reached at 9 mg/m2/day x 5 days.

References

Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyS H Kaufmann
Apr 1, 1989·European Journal of Cancer & Clinical Oncology·P O MulderN H Mulder
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L J van WarmerdamJ H Beijnen
Dec 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E L TrimbleR Hayn
Oct 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyS H Kaufmann
May 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A P KudelkaJ J Kavanagh
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E K RowinskyR C Donehower
Dec 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J CreemersW W Ten Bokkel Huinink
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R MurrenY C Cheng
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M LegrosR Plagne
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J StiffS G Fisher
Jun 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P HoskinsB Zee
Apr 29, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G J RustinK Bertelsen
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W ten Bokkel HuininkUNKNOWN International Topotecan Study Group

❮ Previous
Next ❯

Citations

Dec 11, 2014·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·F SelleJ P Lotz
Oct 27, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Janelle B PerkinsDaniel M Sullivan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

American Journal of Clinical Oncology
C W RyanM J Ratain
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
M Verhaar-LangereisE Witteveen
© 2021 Meta ULC. All rights reserved